65,437 trials
Inflammatory Bowel Disease · Ulcerative Colitis
Primary: Clinical Disease Activity (Seo Index) — 122; 113.6 Units
Scar Prevention · Scar Reduction
Primary: Differences Among the 3 Dosage Groups in the Patient (PSAS) and Observer (OSAS) Scar Assessment Scale (POSAS) Scores — 13.3; 17.7; 15.9; 17.1 Units on a scale — p=0.078
Hypertension
Primary: Percentage of Non-Diabetic and Diabetic Participants Meeting Blood Pressure Targets at 3 Months — 56.0; 28.2 percentage of participants
Type 1 Diabetes Mellitus
Primary: Plasma Glucose (PG) Response to Exercise — 75; 90.5 mg/dL — p=0.791
Pediculosis
Primary: Efficacy of NatrOVA Creme Rinse - 1% Relative to NIX Creme Rinse in Subjects Infested With Head Lice — 77; 19; 40; 14 participants
Candidiasis
Primary: Percentage of Participants With Favorable Outcome — 76.1 percentage of participants
HIV Infections
Primary: Raltegravir Male Genital Tract Concentration — 485.1 ng/mL
Gastroesophageal Reflux Disease
Primary: Change in Frequency of Days With Heartburn From Baseline to 8 Weeks of Treatment — -3.44 Days per week with symptoms
Diabetes Mellitus, Non-Insulin-Dependent
Primary: Number of Participants Who Experienced at Least One Adverse Event — 1; 1; 0; 1 participants
Breast Neoplasm
Primary: Best Overall Response (BOR) — 20.0; 10.3 percentage of participants — p=0.1109
Coronary Artery Disease · Angiotensin Converting Enzyme · Angiotensin Receptor Blockers
Primary: Tissue-type Plasminogen Activator (t-PA) Antigen Response — 14.36; 14.05; 11.97; 27.65 ng/mL — p=0.28
Small Gestational Age (SGA)
Primary: Height Velocity — 6.40; 4.40 centimeter (cm)/year — p=0.001
Herpes Zoster · HIV Infections
Primary: Number of Participants With Composite Safety Endpoint of the Occurrence of Serious Adverse Events (SAEs) or Division of AIDS (DAIDS) Grade 3 and 4 Signs and Symptoms…
Type 2 Diabetes
Primary: Mean Change in Glycosylated Hemoglobin (A1C) — -0.71; -0.94 percentage of Hb — p=0.165
Chemotherapy-Induced Nausea and Vomiting · Ovarian Cancer
Primary: Efficacy of the Aprepitant/Ramosetron/Dexamethasone Regimen in Terms of the Proportion of Patients With a Complete Response (CR) During the 120 Hour Following Initiation…